In a paper published recently in Nature Communications, our team of scientists from Bayer and Schrödinger describe a computational method that efficiently, reliably and accurately predicts all possible polymorphs of a given drug-like small molecule.
化学業界は転換期を迎えており、コペルニック・カタリスト社は、コスト削減、排出量削減、そして飛躍的な効率化を実現する次世代触媒という、業界をリードする技術の開発に取り組んでいます。シュレーディンガー社とのパートナーシップは、特にアンモニア合成において、触媒設計における大きな進歩をもたらしました。明確な推進力と強固な技術基盤を背景に、私たちは現在、本格的な商業展開に向けて事業を拡大しています。
The chemical industry is at a turning point, and Copernic Catalysts is building the technology to lead it—next-generation catalysts that reduce costs, lower emissions, and unlock step-change efficiency. Over the past year, our partnership with Schrödinger has led to significant breakthroughs in catalyst design, particularly in ammonia synthesis. With clear momentum and a strong technical foundation, we’re now scaling toward full commercial deployment.
At Schrödinger, our mission is clear: to improve human health and quality of life by transforming the way therapeutics and materials are discovered. That mission guides everything we do — including how we think about the efficiency of our technology. Computation is the engine that drives our company. Our industry-leading computational platform is licensed by
Sign up to receive quarterly updates with the latest from Extrapolations.
